# Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis

> **NCT04315480** · PHASE2 · UNKNOWN · sponsor: **Università Politecnica delle Marche** · enrollment: 38 (actual)

## Conditions studied

- SARS Pneumonia

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04315480
- **Lead sponsor:** Università Politecnica delle Marche
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-12
- **Primary completion:** 2020-04-09
- **Final completion:** 2020-05
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04315480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04315480, "Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04315480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*